Novo Nordisk makes $1.1bn bid for biopharma company
02-09-2022
Novo Nordisk seeks to block Mylan generic
22-08-2019
Teva enters settlement with Novo Nordisk to sell Victoza generic
19-03-2019
Tada Images / Shutterstock.com
Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza (Liraglutide) before the companies were meant to face trial in April.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Novo Nordisk, Sandoz, Victoza, patent, US District Court for the District of Delaware, Colm Connolly
